Healthcare Realty Trust (HR) has arranged a new US$400 million senior unsecured delayed draw term loan, giving the company committed capital through 2029 with the option to increase the facility by up to US$100 million.

At a share price of US$20.36, Healthcare Realty Trust has seen a 30 day share price return of 8.82% and a year to date share price return of 20.12%. The 1 year total shareholder return of 47.43% points to strong recent momentum, even as the new US$400 million term loan focuses attention on funding flexibility and balance sheet risk.

If this kind of financing story has you thinking about where capital is flowing next, it could be worth scanning for other real assets tied to infrastructure via 35 power grid technology and infrastructure stocks

With HR trading close to analyst targets but sitting on a sizeable intrinsic value gap and fresh debt capacity, should you see a mispriced REIT with room to run or a stock where the market already sees the growth coming?

Most Popular Narrative: 0.5% Undervalued

With Healthcare Realty Trust last closing at $20.36 against a narrative fair value of $20.45, the gap is slim but the underlying story is detailed.

Balance sheet strengthening via significant asset dispositions (focused on non-core, low-growth properties), targeted deleveraging, and a right-sized dividend increases financial flexibility for reinvestment, positioning the company for improved net margins, earnings quality, and greater capital deployment into high-return projects.

Curious what kind of margin shift and earnings profile that balance sheet overhaul is aiming for? The narrative leans on measured revenue growth, sizeable margin rebuild, and a future earnings multiple that has to be justified by those moving parts.

Result: Fair Value of $20.45 (UNDERVALUED)

However, investors still need to weigh execution risks around the operations overhaul and lease-up plans, along with the drag from current losses and leverage.

Another Way To Look At HR

Our DCF model points to a fair value of about $27.60, compared with the current $20.36 share price and the $20.45 analyst target. That is a much larger gap than the 0.5% narrative undervaluation, so which set of assumptions do you trust more?

Next Steps

Seeing both risks and rewards in this story, and wondering how it balances out for you personally? Take a closer look at the data, decide where you stand, and make sure you understand the 1 key reward and 2 important warning signs

Looking for more investment ideas?

If HR has sparked fresh questions about where to put capital next, do not stop here. Broaden your watchlist with a few focused stock ideas.

• Target potential bargains with strong fundamentals by scanning 48 high quality undervalued stocks before the crowd catches up.
• Prioritise resilience first and check which companies stand out in the 65 resilient stocks with low risk scores so sudden shocks do not catch you off guard.
• Hunt for quality that is still off most radars by using the screener containing 21 high quality undiscovered gems and spot opportunities others might be missing.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.